C. Ressayre-Djaffer

发表

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

H. Cario, E. Vichinsky, M. Cappellini, 2007, Clinical therapeutics.

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

P. Marks, O. Onyekwere, P. Swerdlow, 2007, British journal of haematology.

Patient Satisfaction with Deferasirox (Exjade®, ICL670) an Oral Form of Chelation Therapy Versus Deferoxamine an Infused Chelation Therapy.

J. Ford, M. Cappellini, M. Bejaoui, 2005 .

P-113 The efficacy and tolerabilityof ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload

M. Cazzola, P. Greenberg, C. Rose, 2005 .

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

S. Perrotta, P. Marks, M. Cappellini, 2006, Blood.

Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.

S. Perrotta, M. Cappellini, M. Bejaoui, 2004 .

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

J. Ford, P. Brissot, A. Thompson, 2005 .